MedTrace Logo

A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study

NCT07515404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2026-04-07

No results posted yet for this study

Summary

Global demand for therapeutic plasmapheresis is rising to treat various immunological, rheological, and lipoprotein-related disorders. Traditional therapeutic plasma exchange (TPE) removes plasma entirely and replaces it with costly substitution fluids, making it less sustainable. Semi-specific methods like plasma adsorption and double-filtration plasmapheresis (DFPP) avoid this by purifying and reinfusing the patient's own plasma.

DFPP, although effective and widely reimbursed in Europe and Asia, relies on membrane-based plasma separation systems that require high blood flow rates and offer limited plasma extraction efficiency, which prolongs treatment and often necessitates central venous access.

Centrifugation-based systems allow lower blood flow rates and higher plasma extraction ratios, but existing devices are not designed for automated double-cascade plasmapheresis.

To address these limitations, our department has implemented a new strategy: Centrifugation and Filtration Plasmapheresis (CFPP), which combines centrifugation for initial plasma separation with membrane filtration for secondary purification. CFPP maintains the safety and efficacy of DFPP while offering key advantages: easier peripheral venous access, shorter procedures, no need for replacement fluids, and reinfusion of purified autologous plasma.

Conditions

  • Plasmapheresis

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Benjamin SAVENKOFF, MD · CHR Metz-Thionville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-02-01
Completion
2026-02-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07515404 on ClinicalTrials.gov